Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.
Sho T, Suda G, Yamamoto Y, Furuya K, Baba M, Ogawa K, Kubo A, Tokuchi Y, Fu Q, Yang Z, Kimura M, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Suzuki K, Izumi T, Meguro T, Terashita K, Takagi T, Ito J, Kobayashi T, Miyagishima T, Sakamoto N. Sho T, et al. Among authors: takagi t. Cancers (Basel). 2022 Aug 15;14(16):3938. doi: 10.3390/cancers14163938. Cancers (Basel). 2022. PMID: 36010930 Free PMC article.
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria.
Sho T, Suda G, Ogawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Ito J, Yamamoto Y, Kobayashi T, Meguro T, Saga A, Miyagishima T, Terasita K, Takagi T, Kamiyama T, Taketomi A, Sakamoto N. Sho T, et al. Among authors: takagi t. Hepatol Res. 2020 Aug;50(8):966-977. doi: 10.1111/hepr.13511. Epub 2020 Jul 9. Hepatol Res. 2020. PMID: 32562334
Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment.
Sho T, Suda G, Ohara M, Kohya R, Sasaki T, Yoshida S, Hosoda S, Ogawa K, Kitagataya T, Maehara O, Ohnishi S, Kawagishi N, Natsuizaka M, Nakai M, Baba M, Yamamoto Y, Tsukuda Y, Meguro T, Yamada R, Kobayashi T, Takagi T, Sakamoto N; NORTE STUDY GROUP. Sho T, et al. Among authors: takagi t. Target Oncol. 2024 Sep;19(5):769-778. doi: 10.1007/s11523-024-01092-7. Epub 2024 Sep 2. Target Oncol. 2024. PMID: 39222223
Single-stage endoscopic treatment for mild to moderate acute cholangitis associated with choledocholithiasis: a multicenter, non-randomized, open-label and exploratory clinical trial.
Eto K, Kawakami H, Haba S, Yamato H, Okuda T, Yane K, Hayashi T, Ehira N, Onodera M, Matsumoto R, Matsubara Y, Takagi T, Sakamoto N; Hokkaido Interventional EUS/ERCP study (HONEST) group. Eto K, et al. Among authors: takagi t. J Hepatobiliary Pancreat Sci. 2015 Dec;22(12):825-30. doi: 10.1002/jhbp.296. Epub 2015 Nov 25. J Hepatobiliary Pancreat Sci. 2015. PMID: 26510180 Clinical Trial.
Liver metastasis 13 years after the resection of a malignant triton tumor originating in the duodenum.
Ohashi K, Asahi Y, Kamiyama T, Kakisaka T, Orimo T, Nagatsu A, Sakamoto Y, Kamachi H, Takagi T, Otsuka T, Mitsuhashi T, Sugita S, Hasegawa T, Taketomi A. Ohashi K, et al. Among authors: takagi t. Int Cancer Conf J. 2022 Mar 15;11(3):178-183. doi: 10.1007/s13691-022-00544-z. eCollection 2022 Jul. Int Cancer Conf J. 2022. PMID: 35669906 Free PMC article.
Malignant triton tumor of the duodenum: report of a case.
Asahi Y, Nakagawa T, Nakanishi K, Takagi T, Yoshikawa H, Wakizaka K, Yokoyama R, Takahashi M, Sasaki F. Asahi Y, et al. Among authors: takagi t. Int Cancer Conf J. 2018 Mar 13;7(2):52-58. doi: 10.1007/s13691-018-0320-7. eCollection 2018 Apr. Int Cancer Conf J. 2018. PMID: 31149515 Free PMC article.
3,106 results